A gynecologic oncologist with expertise in molecular genetics and personalised medicine. He has worked at the Moffitt Cancer Center in Tampa, Florida for 9 years, where he currently serves as President of the Moffitt Medical Group and Chair of the Department of Women’s Oncology.

James J. Mulé, PhD has been involved in oncology research and the development of cancer treatments for more than 20 years. Dr. Mulé is an Associate Center Director for Translational Research, and the Director of Cell-Based Therapies at Moffitt Cancer Center. Dr. Mulé is a previous founder of two biotech start-up companies while an adjunct faculty member in the Department of Surgery, Stanford University.

Founder and CEO of OvaGene Oncology Inc., Mr. Kiesner is a successful biotech serial entrepreneur with a footprint in this space, and a previous successful exit from Oncotech. Mr. Kiesner has been a partner at Northstar Ventures, General Council and Treasurer of ADC Telecommunications, as well as being President of ADC Corporation’s Magnetic division.

As CEO of Cozint, Mr. Sederman oversaw the development of innovative Web approaches that supported pharmaceutical companies with next-generation research solutions to their sales and marketing concerns. Mr. Sederman has about 20 years of experience in consulting and market research for healthcare companies, and continues to redefine the marketing field for healthcare companies with his ground-breaking insights.

President and CEO of Oncolome Diagnostics. Previously Senior Director of Business Development for Genzyme Corporation with 13 years of industry experience in oncology, personalized medicine, molecular diagnostics and pharmacogenomics. Mr. Cerio has experience with early stage biotechnology companies BG Medicine and Genaissance Pharmaceuticals.